Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030419 | 0.98 | LMNA (0.47) | LMNAMAPTL3MBTL1BRD4KMT2A | |
| SCHEMBL2761583 | 0.93 | EDNRA (0.48) | ABCG2ABCB1EDNRAMAOBBCHE | |
| SCHEMBL2761687 | 0.91 | EDNRA (0.45) | ABCG2ABCB1EDNRAMAOBBCHE | |
| SCHEMBL2761691 | 0.83 | ABCG2 (0.43) | LMNAMAPTL3MBTL1BRD4KMT2A | |
| SCHEMBL2761692 | 0.83 | ABCG2 (0.43) | LMNAMAPTL3MBTL1BRD4KMT2A | |
| SCHEMBL2762251 | 0.83 | BRD4 (0.47) | LMNAMAPTL3MBTL1BRD4KMT2A | |
| SCHEMBL2762090 | 0.77 | EGLN1 (0.47) | LMNAMAPTL3MBTL1MAOBEGLN1 | |
| SCHEMBL2761700 | 0.77 | LMNA (0.43) | LMNAL3MBTL1KMT2AEGLN1MEN1 | |
| SCHEMBL2761617 | 0.76 | EDNRA (0.54) | LMNAMAPTL3MBTL1BRD4RAB9A | |
| SCHEMBL2761752 | 0.76 | PDE4A (0.45) | LMNAKMT2ARAB9AEGLN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | LMNA 2624/4885MAPT 4705/4885L3MBTL1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.